APA (7th ed.) Citation

Zheng, F., Du, F., Wang, W., Wang, Y., Li, M., Zhao, J., . . . Yuan, P. (2022). Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial. Breast Cancer Research and Treatment, 191(1), 97-105. https://doi.org/10.1007/s10549-021-06401-6

Chicago Style (17th ed.) Citation

Zheng, Fangchao, et al. "Updated Efficacy of Adjuvant Epirubicin Plus cyclophosphamide Followed By taxanes Versus Carboplatin Plus taxanes in Early Triple-negative Breast Cancer in Phase 2 Trial." Breast Cancer Research and Treatment 191, no. 1 (2022): 97-105. https://doi.org/10.1007/s10549-021-06401-6.

MLA (9th ed.) Citation

Zheng, Fangchao, et al. "Updated Efficacy of Adjuvant Epirubicin Plus cyclophosphamide Followed By taxanes Versus Carboplatin Plus taxanes in Early Triple-negative Breast Cancer in Phase 2 Trial." Breast Cancer Research and Treatment, vol. 191, no. 1, 2022, pp. 97-105, https://doi.org/10.1007/s10549-021-06401-6.